Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial
PierFranco Conte(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Anita Rimanti(Azienda Ospedaliera Carlo Poma), Federica Miglietta(University of Padua), Samanta Sarti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Alessandra Beano(Presidio Ospedaliero), Sara Balduzzi(Dutch Cancer Society), Santino Minichillo(Azienda USL di Bologna), Roberto Vicini, Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Anna Turletti(Ospedale Martini), Francesco Giotta(Istituto Tumori Bari), Elisa Anselmi(Azienda Unità Sanitaria Locale Piacenza), Maria Vittoria Dieci(Istituto Oncologico Veneto), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Vittorio Gebbia(La Maddalena), Alessio Schirone, Robert D’Amico(University of Modena and Reggio Emilia), Michele Aieta(Centro di Riferimento Oncologico della Basilicata)
Cited by 25
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830